Hosted by the Human Health Therapeutics Research Centre, the Disruptive Technology Solutions for Cell and Gene Therapy Challenge program develops accessible and affordable cell and gene therapies to treat chronic diseases and rare genetic disorders in Canada.
Cell and gene therapies have proven to be effective in targeting and treating chronic diseases and rare genetic disorders, helping many patients in Canada and around the world. Yet these new technologies continue to face significant challenges as they move from the lab into clinical application.
Through our challenge program, we develop technologies and help innovators navigate the complex development pathway toward accessible and affordable cell and gene therapies for Canadian patients.
Areas of focus
Our researchers work with industry, academia and clinical partners to advance research across the Disruptive Technology Solutions for Cell and Gene Therapy Challenge program’s 5 key areas of focus.
- Affordable gene therapies
- CAR T-cell therapy
- Improved engineering adeno-associated virus (AAV) for gene therapy
- Precision editing to create universal donor cells
- Next-generation solid tumour and non-viral gene therapies
News
The latest news and events related to the NRC's Disruptive Technology Solutions for Cell and Gene Therapy Challenge program will be posted here, as they become available.
Featured stories
Contact us
If you are interested in collaborating with us, making investments in this area, or if you have any questions, please contact:
Risini Weeratna
Program Director, Disruptive Technology Solutions
for Cell and Gene Therapy
Challenge Program
The NRC's unique CAR T-cell therapy
Learn more about how the NRC is working to develop cutting-edge, made-in-Canada CAR T-cell therapies.
Related links
Stay connected
Media Relations, National Research Council of Canada
1-855-282-1637
(toll-free in Canada only)
1-613-991-1431
(elsewhere in North America)
001-613-991-1431 (international)
media@nrc-cnrc.gc.ca
Follow us on X: @NRC_CNRC